Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Segment Information (Tables)

v2.4.1.9
Note 4 - Segment Information (Tables)
 9 Months Ended
Mar. 31, 2015
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Quarter Ended
 
 
Nine Months Ended
 
 
 
March 31,
 
 
March 31,
 
 
 
2015
 
 
2014
 
 
2015
 
 
2014
 
Net sales:
                                
Biotechnology
   $ 83,154     $ 80,134     $ 242,573     $ 223,882  
Clinical Controls
     15,368       15,421       43,161       41,358  
Protein Platforms
     15,669       -       49,061       -  
Intersegment
    (33
)
     -       (212
)
     -  
Consolidated net sales
   $ 114,158     $ 95,555     $ 334,583     $ 265,240  
                                 
Segment operating income
                                
Biotechnology
  $ 46,196     $ 46,142     $ 127,426     $ 125,265  
Clinical Controls
    4,610       4,909       12,963       12,614  
Protein Platforms
    (1,710
)
     -       4,461       0  
Subtotal reportable segments
    49,096       51,051       144,850       137,879  
                                 
Cost recognized on sale of acquired inventory
     (897
)
     (1,177
)
     (5,252
)
     (4,312
)
Amortization of acquisition related intangible assets
     (6,751
)
     (2,605
)
     (19,337
)
     (7,380
)
Acquisition related expenses
     (335
)
     (395
)
     (3,906
)
     (927
)
Corporate general and administrative expenses
     (1,687
)
     (1,105
)
     (7,133
)
     (4,356
)
Consolidated operating income
   $ 39,426     $ 45,769     $ 109,222     $ 120,904